Her-2 amplification
indicates a bad prognosis, short survival time, and the
existence of a more aggressive phenotype of tumor
cells. Her-2 overexpressed breast cancer may be resistant to endocrine therapy and some chemotherapies;
however, it is sensitive to Herceptin treatment and
exhibits more responsiveness to paclitaxel and anthracyclines [55]. At present, there are both IHC and FISH
assays for measuring Her-2 overexpression. The former
assay is simplistic, convenient, and cost-saving, but it
can be affected by various factors and the staining
result could be ambiguous. The latter is relatively
sophisticated and expensive, but the staining result is
more accurate. Therefore, the FISH assay is regarded as
the gold standard for clinical evaluation of the Her-2
status and is generally recommended in when the IHC
result could not clarify the Her-2 status.
Her-2 amplificationindicates a bad prognosis, short survival time, and theexistence of a more aggressive phenotype of tumorcells. Her-2 overexpressed breast cancer may be resistant to endocrine therapy and some chemotherapies;however, it is sensitive to Herceptin treatment andexhibits more responsiveness to paclitaxel and anthracyclines [55]. At present, there are both IHC and FISHassays for measuring Her-2 overexpression. The formerassay is simplistic, convenient, and cost-saving, but itcan be affected by various factors and the stainingresult could be ambiguous. The latter is relativelysophisticated and expensive, but the staining result ismore accurate. Therefore, the FISH assay is regarded asthe gold standard for clinical evaluation of the Her-2status and is generally recommended in when the IHCresult could not clarify the Her-2 status.
การแปล กรุณารอสักครู่..
